课题基金 / 基金详情

INTERFERON A--PROLONGATION OR PERMANENCE OF THE HONEYMOON PERIOD IN DIABETES

INTERFERON A--PROLONGATION OR PERMANENCE OF THE HONEYMOON PERIOD IN DIABETES
干扰素 A——糖尿病蜜月期的延长或持久
批准号：
6309257
负责人：
STALEY armstrong BROD
金额：
$1.51万
依托单位：
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2001-02-28
来源：
https://reporter.nih.gov/project-details/6309257
关键词：
clinical research clinical trial phase I diabetes mellitus therapy human subject human therapy evaluation immunotherapy insulin dependent diabetes mellitus interferon alpha oral administration pancreatic islet function

项目摘要

项目成果

STALEY armstrong BROD的其他基金

相似基金

相关文献

中文摘要
翻译
这是一项口服干扰素-α治疗胰岛素依赖型糖尿病(IDDM)的I-II期试验，IDDM是一种自身免疫疾病。它将研究干扰素-α对IDDM患者免疫功能和β细胞功能及破坏的影响。新诊断为IDDM的受试者将参加为期12个月的治疗。服用干扰素-a的临床改善或免疫抑制的建立可能导致安慰剂对照的II-III期试验，临床疾病的持续改善是主要结果。
英文摘要
This is a phase I-II trial of ingested interferon-alpha (IFN-a) in insulin dependent diabetes mellitus (IDDM), an autoimmune disease. It will study the effect of IFN-a on immune function and Beta cell function and destruction in IDDM. Subjects with newly diagnosed IDDM will be enrolled for a treatment period of up to 12 months. Establishment of clinical improvement or immunosuppression with ingested IFN-a may lead to a placebo-controlled phase II-III trial with persistent improvement in clinical disease as a primary outcome.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IFNA: PROLONGATION OR PERMANENCE OF THE "HONEYMOON" PHASE IN DIABETES MELLITUS
PREVENTION OF COGNITIVE DECLINE IN ALZHEIMER'S DISEASE VIA INGESTED IFN-ALPHA
PROTEIN BIOMARKERS OF IFN-ALPHA IN MS
INGESTED IFN-A: PROLONGATION OR PERMANENCE OF THE "HONEYMOON" PHASE IN DIABETES
海外基金